Meal Glycaemic Index and Exercise After Gastric Bypass
The Importance of Glycaemic Index and Exercise on Postprandial Glucose Excursions and Gut Hormone Secretion Following Roux-en-Y Gastric Bypass
1 other identifier
interventional
20
1 country
1
Brief Summary
The study will evaluate postprandial glucose excursions and gut hormone secretion after ingestion of meals with different glycaemic index (GI) values (high vs low) followed by an acute bout of exercise or rest in gastric bypass operated subjects and matched control subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2018
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 6, 2018
CompletedStudy Start
First participant enrolled
March 1, 2018
CompletedFirst Posted
Study publicly available on registry
March 27, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2020
CompletedJune 15, 2023
June 1, 2023
2 years
February 6, 2018
June 13, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Impact of acute bout of exercise on nadir plasma glucose within groups for each intervention
Comparison of nadir plasma glucose in response to an acute bout of exercise internally in groups a) RYGB and b) control group
The lowest plasma glucose concentration at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210 OR 240 min after ingestion of meal
Impact of glycaemic index on nadir plasma glucose within groups for each intervention
Comparison of nadir plasma glucose in response to meals with high vs low glycaemic index internally in groups a) RYGB and b) control group
The lowest plasma glucose concentration at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210 OR 240 min after ingestion of meal
Secondary Outcomes (17)
Impact of acute bout of exercise on AUC glucose within groups
AUC time-concentration-curve for plasma glucose from 0, 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal
Impact of acute bout of exercise on delta-fasting-peak glucose within groups
Difference between fasting plasma glucose and highest plasma glucose at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal
Impact of glycaemic index on AUC glucose within groups
AUC time-concentration-curve for plasma glucose from 0, 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal
Impact of glycaemic index on delta-fasting-peak glucose within groups
Difference between fasting plasma glucose and highest plasma glucose at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal
Impact of postprandial exercise and meal glycaemic index on glucagon-like peptide-1 (GLP-1) secretion within the groups determined by differences in AUC
AUC for time concentration curve of GLP-1 at 0, 10, 20, 30, 35, 60, 90, 120, 150, 180, 240 min after ingestion of meal
- +12 more secondary outcomes
Other Outcomes (19)
Between group differences in delta-fasting-to-peak glucose for each intervention
difference between fasting glucose and highest glucose concentration at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal
Between group differences in delta-peak-nadir glucose for each intervention
Difference from highest plasma glucose to subsequent lowest plasma glucose at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal
Between group differences in nadir plasma glucose for each intervention
Lowest glucose at 5, 10, 15 ,20, 30, 45, 60, 70, 80, 90, 100, 110, 120, 135, 150, 180, 210, 240 min after ingestion of meal
- +16 more other outcomes
Study Arms (2)
10 Roux-en-Y Gastric Bypass patients
EXPERIMENTAL4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
10 control subjects
EXPERIMENTAL4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
Interventions
Meal with low glycaemic index (GI) is consumed over 20 min
Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
Meal with high glycaemic index (GI) is consumed over 20 min
Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
Eligibility Criteria
You may qualify if:
- Achieved \> 50% Excess BMI Loss
- Weight stability (no fluctuations over ± 5 kg the last 3 months)
- HBA1c \< 48 mmol/mol before and after surgery without the use of anti-diabetic medication
- The participant must be able to ingest the meals
You may not qualify if:
- Low hemoglobin levels (\< 6.5 mM)
- Pregnancy (determined by human chorionic gonadotropin (hCG) test) or breastfeeding
- Dysregulated thyroid gland affection
- The use of medication which affects heart frequency (i.e. Beta-blockers)
- Complications following RYGB consisting of dysphagia or other problems associated with ingestion of normal foods (i.e. vomit, diarrhea or strong abdominal pain).
- Control group:
- Matched with the RYGB patients on gender, age (± 5 years), menopausal state (pre- versus post-menopausal) and BMI (± 3 points).
- Weight stable ( ± 5 kg during 3 months)
- HBA1c \< 48 mmol/mol
- Prior bariatric surgery or prior surgery in the upper gastrointestinal tract.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kirstine Nyvold Bojsen-Moellerlead
- University of Copenhagencollaborator
Study Sites (1)
Department of Endocrinology, Hvidovre Hospital
Hvidovre, DK-2650, Denmark
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kirstine N Bojsen-Moller, MD, PhD
Department of Endocrinology, Hvidovre Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Kirstine Nyvold Bojsen-Moeller
Study Record Dates
First Submitted
February 6, 2018
First Posted
March 27, 2018
Study Start
March 1, 2018
Primary Completion
March 1, 2020
Study Completion
March 1, 2020
Last Updated
June 15, 2023
Record last verified: 2023-06